German Accelerator Life Sciences (GALS) Partner Ada Health Expands to the US Upon Closing $47M Funding Round

German Accelerator Life SciencesAI health companion, Ada Health intensifies collaboration with German Accelerator Life Sciences (GALS) as it expands to the US. Following the successful closing of a $47M funding round, Ada will accelerate operational and partnership developments in a rapidly growing US market. The London and Berlin-based health technology company has developed a health companion and telemedicine app as well as a decision support tool for medical professionals, which launched in late 2016. With its sophisticated AI engine paired to a vast medical knowledge base, Ada has become one of the fastest growing medical apps in 2017, with over 1.5M people using Ada to assess their health. This rapid growth is reflected by the substantial $47M financial backing they secured from lead investor Access Industries, and including the AI entrepreneur behind Amazon Alexa, William Tunstall-Pedoe and Google's Chief Business Officer Philipp Schindler.

The German Accelerator Life Sciences (GALS) program, an initiative supported by the German Federal Ministry of Economic Affairs (BMWi), will advise on the development and implementation of Ada’s US market strategy with its experienced mentor team and extensive network of partners and industry experts.

"The US has become one of our fastest growing markets," said Daniel Nathrath, CEO and Founder of Ada. "Our operational expansion, along with our new team of medical advisors and collaboration with GALS, will help us identify the most effective ways to integrate our solution into the US healthcare ecosystem and maximise the impact we deliver to patients."

"Healthcare systems are under extreme pressure," added Dr. Claire Novorol, Founder and Chief Medical Officer of Ada. "There's a tremendous potential for Ada’s assessment technology to improve personalized health support and positively transform the way in which patients and doctors interact, in the US and globally."

"We believe Ada is positioned to become a leading global health management player," commented Christoph Lengauer, CEO of the German Accelerator. "GALS is excited to be collaborating with Ada on this expansion into the US. We will leverage our deep industry network and expertise to support their continued success."

"Ada has developed one of the most highly innovative and sophisticated health assessment tools on the market," commented Thomas Kiessling, GALS mentor and former Chief Product and Innovation Officer at Deutsche Telekom. "We see many potential opportunities where Ada can add value to the US life sciences industry."

Ada's personal health companion interacts with patients via a conversational interface to identify their symptoms and suggest possible causes. As a follow up, patients in the UK have the option to remotely consult with a general practitioner through Ada's Doctor Chat. The German version of the App was launched early this month and aims to follow the extended UK model in the near future.

As part of the European Union's Horizon 2020 Research and Innovation Programme (Ada2020), Ada has also developed a decision support tool for general practitioners and specialists. After years of years refining our medical content and reasoning capabilities, along with continuous learning from medical experts, Ada provides an advanced decision support system and is now able to support doctors with their diagnosis for even the most complex and rare cases.

About Ada

Ada Health is an innovative health technology company that believes everyone in the world should have access to quality, personalized health information and care. Developed by a team of doctors, scientists and engineers, Ada Health launched its conversational health companion app to empower people with personalized medical insights and identify appropriate next steps. Supported by a sophisticated AI engine and curated medical knowledge base, Ada also augments doctors by providing earlier health information and decision support. Ada's personal health companion app is available on iOS and Android and has been one of the fastest growing medical apps in 2017, ranked #1 in over 130 countries. You can find more information about Ada at www.ada.com.

About the German Accelerator Life Sciences

The German Accelerator Life Sciences (GALS) is an initiative of the German Federal Ministry for Economic Affairs and Energy (BMWi) with the goal of helping German startups and young companies succeed in the global marketplace. GALS, centrally located and highly connected in the world’s leading life sciences innovation hub in Cambridge, Massachusetts, offers support in multiple areas: from operational assistance to high end mentoring and strategic guidance by experienced industry experts and key opinion leaders.

Most Popular Now

SPARK TSL Acquires Sentean Group

SPARK TSL is acquiring Sentean Group, a Dutch company with a complementary background in hospital entertainment and communication, and bringing its Fusion Bedside platform for clinical and patient apps to...

Can AI Techniques Help Clinicians Assess…

Investigators have applied artificial intelligence (AI) techniques to gait analyses and medical records data to provide insights about individuals with leg fractures and aspects of their recovery. The study, published in...

AI Makes Retinal Imaging 100 Times Faste…

Researchers at the National Institutes of Health applied artificial intelligence (AI) to a technique that produces high-resolution images of cells in the eye. They report that with AI, imaging is...

Standing Up for Health Tech and SMEs: Sh…

AS the new chair of the health and social care council at techUK, Shane Tickell talked to Highland Marketing about his determination to support small and innovative companies, by having...

GPT-4 Matches Radiologists in Detecting …

Large language model GPT-4 matched the performance of radiologists in detecting errors in radiology reports, according to research published in Radiology, a journal of the Radiological Society of North America...

ChatGPT Extracts Data for Ischaemic Stro…

In an ischaemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer be supplied with blood as a result. Doctors must...

Experts Propose Specific and Suited Guid…

Current Artificial Intelligence (AI) models for cancer treatment are trained and approved only for specific intended purposes. GMAI models, in contrast, can handle a wide range of medical data including...

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...